Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Blood (2023) 142 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2023-184586

Published: 2023

Journal Articles

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 3603–3605.

https://doi.org/10.1182/blood-2022-166535

Published: 2022

Journal Articles

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-138563

Published: 2020

Journal Articles

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142818

Published: 2020

Journal Articles

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Laura Maria Fogliatto, MD PhD, Cristiana Solza, MD PhD, Alexandre Gustavo Apa, MD, Gustavo HR Magalhaes, MD MSc, Marcia Torresan Delamain, MD, Renato Tavares, MD, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2019) 134 (Supplement_1): 5851.

https://doi.org/10.1182/blood-2019-121960

Published: 2019

Journal Articles

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Fernanda F Engelbrecht, Eliana C Miranda, PhD, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 2938.

https://doi.org/10.1182/blood-2019-129388

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Outcomes of HIV-Associated Burkitt Lymphoma in Brazil: High Treatment Toxicity and Refractoriness Rates - a Multicenter Cohort Study

Wellington F Silva, MD, Pedro Marques Garibaldi, MD, Lidiane Inês Da Rosa, MD, Marcelo Bellesso, MD, Diego V Clé, MD PhD, Marcia Torresan Delamain, MD, Eduardo M Rego, MD PhD, Juliana Pereira, MD PhD, Vanderson Rocha, MD PhD

Blood (2019) 134 (Supplement_1): 1616.

https://doi.org/10.1182/blood-2019-129627

Published: 2019

Journal Articles

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

Blood (2019) 134 (10): 798–801.

https://doi.org/10.1182/blood.2019001088

Published: 2019

Includes: Supplemental data

Journal Articles

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Matheus Sebastian Da Silva, Eliana C Miranda, Marcia Torresan Delamain, MD, Gislaine Oliveira Duarte, MD, Bruna R Vergilio, Ana Beatriz Pascoal Lopes, Jessica CN Vianna, Carmino Antonio De Souza, MD PhD, Erich Vinicius De Paula, MD PhD, Katia B Pagnano, MD

Blood (2018) 132 (Supplement 1): 1749.

https://doi.org/10.1182/blood-2018-99-114036

Published: 2018

Journal Articles

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

Blood (2018) 132 (Supplement 1): 393.

https://doi.org/10.1182/blood-2018-99-115827

Published: 2018

Journal Articles

A Prospective Study Comparing 99m tc-Sestamibi SPECT/CT with 18 f-FDG PET/CT in Multiple Myeloma Staging: A Potential Resource-Constraint Image Alternative for MM Bone Evaluation

Camila Mosci, MD, Fernando Vieira Pericole, MD PhD, Allan de Oliveira Santos, MD, Mariana Cunha Lima, Elba Cristina Camargo Etchebehere, Barbara Juarez Amorim, Gislaine Borba Duarte, MD, Marcia Torresan Delamain, MD, Carmino Antonio Souza, MD PhD, Irene Lorand-Metze, MD PhD, Celso Dario Ramos, MD PhD

Blood (2018) 132 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2018-99-118228

Published: 2018

Journal Articles

Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 1493.

https://doi.org/10.1182/blood.V130.Suppl_1.1493.1493

Published: 2017

Journal Articles

A Randomized, Double-Blind, Phase III Study Comparing Proposed Biosimilar Rituximab (RTXM83) Versus Reference Rituximab, Both in Combination with CHOP, in the First Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Myrna Candelaria, MDPharmD, Derlis Emilio Gonzalez, MD, Surender Kumar Beniwal, MD DM, Lokanatha Dasappa, MD, Daniel Oscar Bar, MD, Marcia Torresan Delamain, Ashis Mukhopadhyay, MD, David Hugo Flores, MD, Dinesh Bhurani, MD DM, FRCPA, Venkatraman Radhakrishnan, MD DM, Alejandro Salvatierra, MD, Ruben Dario Kowalyszyn, MD, Oleg Lipatov, MD, Moosa Patel, MD, Sergio Schusterschitz, MD, Elena Volodicheva, MD, Luis Antonio Perez, MD

Blood (2017) 130 (Supplement 1): 1556.

https://doi.org/10.1182/blood.V130.Suppl_1.1556.1556

Published: 2017

Journal Articles

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Katia B Pagnano, MD, Eliana C Miranda, Marcia Torresan Delamain, Gislaine Oliveira Duarte, MD, Bruna Virgilio, Jessica Vianna, Erich Vinicius De Paula, MD PhD, Carmino Antonio De Souza, MD PhD

Blood (2017) 130 (Supplement 1): 1595.

https://doi.org/10.1182/blood.V130.Suppl_1.1595.1595

Published: 2017

Journal Articles

VEGF , VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

Leisa Lopes-Aguiar, Marcia Torresan Delamain, Angelo Borsarelli Carvalho Brito, Gustavo Jacob Lourenço, Ericka Francislaine Dias Costa, Gislaine Borba Oliveira, Jose Vassallo, Carmino Antônio De Souza, MD PhD, Carmen Silvia Passos Lima

Blood (2016) 128 (22): 4457.

https://doi.org/10.1182/blood.V128.22.4457.4457

Published: 2016

Journal Articles

Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi

Blood (2015) 126 (23): 2686.

https://doi.org/10.1182/blood.V126.23.2686.2686

Published: 2015

Journal Articles

Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis

Guilherme Rossi Assis de Mendonça, Rodrigo de Andrade Natal, Bruna de Albuquerque Murbach, Marcia Torresan Delamain, MD, Carmino Antônio De Souza, MD PhD, Carlos Lenz Cesar, PhD, Jose Vassallo, MD PhD

Blood (2015) 126 (23): 5000.

https://doi.org/10.1182/blood.V126.23.5000.5000

Published: 2015

Journal Articles

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Cintia Do Couto Mascarenhas, PhD, Maria Helena Almeida, PhD, Eliana C M Miranda, MEd, Bruna Virgilio, Marcia Torresan Delamain, MD, Gislaine O. Duarte, PhD, Vagner O Duarte, Carmino A De Souza, Sr., MD, PhD, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 4041.

https://doi.org/10.1182/blood.V122.21.4041.4041

Published: 2013

NARROW

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Outcomes of HIV-Associated Burkitt Lymphoma in Brazil: High Treatment Toxicity and Refractoriness Rates - a Multicenter Cohort Study

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

A Prospective Study Comparing 99m tc-Sestamibi SPECT/CT with 18 f-FDG PET/CT in Multiple Myeloma Staging: A Potential Resource-Constraint Image Alternative for MM Bone Evaluation

Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi

A Randomized, Double-Blind, Phase III Study Comparing Proposed Biosimilar Rituximab (RTXM83) Versus Reference Rituximab, Both in Combination with CHOP, in the First Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

VEGF , VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi

Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only